回输采集物成分对恶性血液病异基因造血干细胞移植预后的影响

Tolerability of Asciminib vs Investigator-Selected (IS) Tyrosine Kinase Inhibitors (TKIs) in the Phase 3 ASC4FIRST Study in Newly Diagnosed Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

重型/极重型再生障碍性贫血(V/SAA)和输血依赖性非重度再生障碍性贫血(TD-NSAA)患者体细胞基因突变及其对免疫抑制治疗(IST)疗效的影响

Identifying mortality-related risk factors of bloodstream infections due to Escherichia coli and Klebsiella pneumoniae in hematological patients

The Value of Peripheral Blood Lymphocyte Subsets in Predicting the Prognosis of Newly Diagnosed Multiple Myeloma

Double-hit and triple-hit multiple myeloma: the clinical manifestation, response and outcome of patients with ultra high-risk cytogenetic abnormalities

FLT3抑制剂在复发难治 AML中诊疗进展

A Novel JAK1 Inhibitor SHR0302 Combined with Prednisone for First-Line Treatment of Chronic Graft-versus-Host Disease: a Phase I Clinical Trial

Prime CAR-T细胞治疗R/R B细胞肿瘤单中心数据分享

Multicenter Data Analysis of Discontinuation of Chronic Myeloid Leukemia Treatment with Tyrosine Kinase Inhibitors in China

Zanubrutinib combined with R-CHOP Regimen in the treatment of untreated Non-Germinal Center B-Cell subtype Diffuse large B-cell lymphoma with multiple extranodal involvement.

造血干细胞移植后CMV特异性T细胞在来特莫韦预防中的重建特征